多发性骨髓瘤髓外病变诊治进展

[1]	Anderson KC.Progress and paradigms in multiple myeloma[J].Clin Cancer Res, 2016, 22:5419-5427.
[2]	Varettoni M, Corso A, Pica G, et al.Incidence, presenting features and outcome of extramedullary disease in multiple myeloma:a longitudinal study on 1003 consecutive patients[J].Ann Oncol, 2010, 21:325-330.
[3]	Pour L, Sevcikova S, Greslikova H, et al.Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse[J].Haematologica, 2014, 99:360-364.
[4]	Rajkumar SV, Dimopoulos MA, Palumbo A, et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol, 2014, 15:e538-e548.
[5]	Gordon AJ, Churg J.Visceral involvement in multiple myeloma[J].N Y State J Med, 1949, 49:282.
[6]	Hayes DW, Bennett WA, Heck FJ.Extramedullary lesions in multiple myeloma;review of literature and pathologic studies[J].AMA Arch Pathol, 1952, 53:262-272.
[7]	Gagelmann N, Eikema DJ, Lacobelli S, et al.Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation:a study from the Chronic Malignancies Working Party of the EBMT[J].Haematologica, 2018, 103:890-897.
[8]	Varga C, Xie W, Laubach J, et al.Development of extramedullary myeloma in the era of novel agents:no evidence of increased risk with lenalidomide-bortezomib combinations[J].Br J Haematol, 2015, 169:843-850.
[9]	Usmani SZ, Heuck C, Mitchell A, et al.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents[J].Haematologica, 2012, 97:1761-1767.
[10]	Minnema MC, van de Donk NW, Zweegman S, et al.Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome[J].Bone Marrow Transplant, 2008, 41:779-784.
[11]	Bladé J, Fernández de Larrea C, Rosinol L, et al.Soft-tissue plasmacytomas in multiple myeloma:incidence, mechanisms of extramedullary spread, and treatment approach[J].J Clin Oncol, 2011, 29:3805-3812.
[12]	Touzeau C, Moreau P.How I treat extramedullary myeloma[J].Blood, 2016, 127:971-976.
[13]	Mangiacavalli S, Pompa A, Ferretti V, et al.The possible role of burden of therapy on the risk of myeloma extramedullary spread[J].Ann Hematol, 2017, 96:73-80.
[14]	Azab AK, Hu J, Quang P, et al.Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features[J].Blood, 2012, 119:5782-5794.
[15]	Weinstock M, Aljawai Y, Morgan EA, et al.Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation[J].Br J Haematol, 2015, 169:851-858.
[16]	Short KD, Rajkumar SV, Larson D, et al.Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma[J].Leukemia, 2011, 25:906-908.
[17]	Rasche L, Bernard C, Topp M, et al.Features of extramedullary myeloma relapse:high proliferation, minimal marrow involvement, adverse cytogenetics:a retrospective single-center study of 24 cases[J].Ann Hematol, 2012, 91:1031-1037.
[18]	Besse L, Sedlarikova L, Greslikova H, et al.Cytogenetics in multiple myeloma patients progressing into extramedullary disease[J].Eur J Haematol, 2016, 97:93-100.
[19]	Deng S, Xu Y, An G, et al.Features of extramedullary disease of multiple myeloma:high frequency of P53 deletion and poor survival:a retrospective single-center study of 834 cases[J].Clin Lymphoma Myeloma Leuk, 2015, 15:286-291.
[20]	Billecke L, Murga Penas EM, May AM, et al.Cytogenetics of extramedullary manifestations in multiple myeloma[J].Br J Haematol, 2013, 161:87-94.
[21]	Wang SY, Hao HL, Deng K, et al.Expression levels of phosphatase and tensin homolog deleted on chromosome 10(PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration[J].Leuk Lymphoma, 2012, 53:1162-1168.
[22]	Sheth N, Yeung J, Chang H.p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma[J].Leuk Res, 2009, 33:1357-1360.
[23]	Sevcikova S, Minarik J, Stork M, et al.Extramedullary disease in multiple myeloma-controversies and future directions[J].Blood Rev, 2019 Apr 13.pii:S0268-960X(18)30096-1.doi:10.1016/j.blre.2019.04.002.[Epub ahead of print].
[24]	Lonial S, Boise LH, Kaufman J.How I treat high-risk myeloma[J].Blood, 2015, 126:1536-1543.
[25]	Weinstock M, Ghobrial IM.Extramedullary multiple myeloma[J].Leuk Lymphoma, 2013, 54:1135-1141.
[26]	Moreau P, Cavo M, Sonneveld P, et al.Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del (17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death[J].J Clin Oncol, 2014, 32:2173-2180.
[27]	Wu P, Davies FE, Boyd K, et al.The impact of extramedullary disease atpresentation on the outcome of myeloma[J].Leuk Lymphoma, 2009, 50:230-235.
[28]	Pérez-Simón JA, Sureda A, Fernández-Aviles F, et al.Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients[J].Leukemia, 2006, 20:542-545.
[29]	Sonneveld P, Avet-Loiseau H, Lonial S, et al.Treatment of multiple myeloma with high-risk cytogenetics:a consensus of the International Myeloma Working Group[J].Blood, 2016, 127:2955-2962.
[30]	Avet-Loiseau H, Fonseca R, Siegel D, et al.Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma[J].Blood, 2016, 128:1174-1180.
[31]	Leleu X, Karlin L, Macro M, et al.Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14):IFM 2010-02 trial results[J].Blood, 2015, 125:1411-1147.
[32]	Bladé J, de Larrea CF, Rosinol L.Extramedullary involvement in multiple myeloma[J].Haematologica, 2012, 97:1618-1619.
[33]	Lonial S, Weiss BM, Usmani SZ, et al.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS):an open-label, randomised, phase 2 trial[J].Lancet, 2016, 387:1551-1560.
[34]	Mi JQ, Fan XH, Xu J, et al.Effective treatment of relapsed/refractory multiple myeloma including extramedullary involvement by BCMA-specific chimeric antigen receptor-modified T cells[J].Blood, 2017, 130:abstract 3115.
[35]	Caers J, Paiva B, Zamagni E, et al.Diagnosis, treatment, and response assessment in solitary plasmacytoma:updated recommendations from a European Expert Panel[J].J Hematol Oncol, 2018, 11:10.
[36]	Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma:A Report From International Myeloma Working Group[J].J Clin Oncol, 2015, 33:2863-2869.
[37]	安娜, 申曼, 李新, 等.异环磷酰胺联合脂质体多柔比星、地塞米松方案治疗复发/难治多发性骨髓瘤临床观察[J].中华医学杂志, 2016, 96(44):3573-3576.
[38]	Patel UH, Drabick JJ, Malysz J, et al.Nonsecretory and light chain escape in patients with multiple myeloma[J].Clin Lymoma Myeloma Leuk, 2018, 18:e515-e519.